Evidence map›Paper›PMID 38567164›Full record

ArticleBioMed research international2024

An

Ismail Adeniran, Hafsa Wadee, Hans Degens

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. AnBioMed research international · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Ismail AdeniranCentre for Advanced Computational Science, Manchester Metropolitan University, Manchester M15 6BH, UK.ORCID https://orcid.org/0000-0002-9775-3249
Hafsa WadeeCentre for Advanced Computational Science, Manchester Metropolitan University, Manchester M15 6BH, UK.ORCID https://orcid.org/0009-0001-1064-7751
Hans DegensDepartment of Life Sciences, Manchester Metropolitan University, Manchester M15 6BH, UK.ORCID https://orcid.org/0000-0001-7399-4841
Manchester Metropolitan University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertrophic cardiomyopathy (HCM) is characterised by asymmetric left ventricular hypertrophy, ventricular arrhythmias, and cardiomyocyte dysfunction that may cause sudden death. HCM is associated with mutations in sarcomeric proteins and is usually transmitted as an autosomal-dominant trait. The aim of this

Indexed as

Cardiomyopathy, HypertrophicMyocytes, CardiacAdenosine TriphosphateCalcium-Calmodulin-Dependent Protein Kinase Type 2Calcium SignalingDeath, SuddenHumansMutationAdenosine TriphosphateCalcium-Calmodulin-Dependent Protein Kinase Type 2

Identifiers

PMID38567164
PMCPMC10985279
OpenAlexW4394749645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.